Restart Life Sciences Corp. NMLSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 337.40K | 98.10K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 337.40K | 98.10K | -- | -- | -- |
| Cost of Revenue | 197.70K | 52.90K | -- | -- | -- |
| Gross Profit | 139.60K | 45.20K | -- | -- | -- |
| SG&A Expenses | 1.40M | 720.80K | 917.30K | 899.50K | 865.20K |
| Depreciation & Amortization | 10.20K | 3.80K | 1.20K | 1.30K | 1.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.61M | 781.30K | 922.10K | 904.40K | 870.20K |
| Operating Income | -1.27M | -683.20K | -922.10K | -904.40K | -870.20K |
| Income Before Tax | -1.24M | -650.80K | -983.60K | -870.70K | -380.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.24 | -0.65 | -0.98 | -0.87 | -0.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.24M | -650.80K | -983.60K | -870.70K | -380.60K |
| EBIT | -1.27M | -683.20K | -922.10K | -904.40K | -870.20K |
| EBITDA | -1.27M | -681.30K | -920.70K | -902.90K | -868.60K |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.03 | 0.00 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.02 | -0.04 | -0.04 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 192.44M | 165.28M | 135.49M | 112.88M | 91.82M |
| Average Diluted Shares Outstanding | 192.44M | 165.28M | 135.49M | 114.71M | 94.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |